Prostate Cancer Genomic Classifier VL

Precision Risk Assessment in Prostate Cancer: Growing Utility in NCCN Guidelines - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen discuss the 2024 updates to the NCCN Prostate Cancer Guidelines, highlighting the integration of the Decipher Genomic Classifier tests across various stages of prostate cancer management. This detailed conversation explores the progression from the 2023 guidelines, emphasizing the evolution of risk stratification tools from prognostic to the now predictive capabilit...

Deciphering Prostate Cancer: How Genomic Biomarkers are Shaping Treatment Decisions - Paul Nguyen

Details
Neil Desai and Paul Nguyen discuss the integration of the Decipher genomic biomarker in prostate cancer treatment. The conversation centers on two trials, NRG-GU009 and GU010, which utilize Decipher genomic classifiers to tailor treatment intensity, particularly in hormonal therapy. Dr. Nguyen emphasizes the shift from traditional metrics like PSA and Gleason scores to more precise genomic classif...

Correlation and Validation of Gene Expression Classifiers in Prostate Cancer: A Large-Scale Study - Daniel Spratt

Details
Aditya Bagrodia hosts Daniel Spratt to discuss the complexities of gene expression classifiers in prostate cancer. Dr. Spratt's team conducted a study involving over 50,000 patients to evaluate the interchangeability of three major gene classifiers: Decipher, Oncotype, and Polaris. Contrary to common belief, the study reveals that these tests are not functionally interchangeable, showing only mode...

Decipher Scores and PSMA PET Imaging: A Correlative Study in High-Risk Prostate Cancer - Amar Kishan

Details
Daniel Spratt engages with Amar Kishan about the role of transcriptomic profiling and PSMA PET imaging in prostate cancer. Dr. Kishan discusses a study involving 18 trials and 12,500 patients, which suggests that extra-prostatic disease is often the driver of distant metastasis in high-risk patients. The study also explores the correlation between Decipher scores and the risk of upstaging on PSMA...

A Comprehensive Look at Genomic Classifier Performance in Intermediate Risk Prostate Cancer: Insights from the NRG Oncology/RTOG 01-26 Trial, Journal Club - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen discuss the publication on genomic classifier performance in intermediate-risk prostate cancer, focusing on the results of the NRG Oncology/RTOG 01-26 randomized Phase 3 trial. The study explores the use of the Decipher 22-gene genomic classifier in risk stratification, outperforming other common risk classification systems for prostatectomy and pre-treatment biopsy...

Risk Assessment in Localized Prostate Cancer - Insights from Real-World Data and SEER Registry - Jim Hu

Details
Ashley Ross and Jim Hu discuss the use of genomic classifiers, specifically the Decipher Genomic Classifier, in the management of localized prostate cancer. They review its performance in larger datasets and its association with prostate cancer outcomes. The conversation also delves into the use of the Decipher Prostate Biopsy Test in men with favorable risk disease undergoing conservative managem...

Active Surveillance: Optimizing the Quality of Life in Men with Localized Prostate Cancer - Preston Sprenkle & Randy Vince

Details
Preston Sprenkle and Randy Vince join Ashley Ross to discuss active surveillance and the benefits of risk stratification for localized prostate cancer. They collectively emphasize the importance of monitoring cancer closely and intervening with curative intent if it becomes aggressive while minimizing morbidity and improving quality of life. Dr. Vince highlights the Michigan Urological Surgery Imp...

Integrating the Use of Prostate Genomic Classifiers into Clinical Practice - A Clinical Pathway Approach - Katie Murray and Anne Lizardi-Calvaresi

Details
Katie Murray and Anne Lizardi-Calvaresi discuss a clinical pathway approach for using the Decipher prostate cancer genomic classifier. Reviewing the level-one evidence described in the NCCN guidelines, they discuss best practices as clinicians integrate prostate cancer genomic classifiers into the care of their patients. They highlight how the test is integrated into the workflow for patient navig...

Transcriptome-Based Prognostic and Predictive Biomarker Analysis - The DECIPHER Genomic Classifier for Prostate Cancer - Ashley Ross

Details
Alicia Morgans and Ashley Ross discuss how the Decipher prognostic biomarker prostate classifier is being integrated into phase II and III clinical trials, a 22-gene prognostic biomarker that provides a score that indicates the aggressiveness of an individual patient’s cancer, to help healthcare professionals more accurately categorize risk and select appropriate treatment. The pair highlights dat...

The Use of Genomics in Unfavorable Intermediate-risk Prostate Cancer - David Morris

Details
David Morris joins Ashley Ross in a conversation on genomics in prostate cancer specifically, in the unfavorable intermediate-risk patient. Drs Morris and Ross highlight the use of genomics in decision-making when considering what the best treatment option is for this group of individuals. They are particularly interested in determining if any of these intermediate-risk patients might actually be...